You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update

Article metrics

Article menu

Download PDFPDF

Late-breaking abstracts
Clinical trials in-progress
798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update

 

Online download statistics by month:

Online download statistics by month: November 2020 to July 2025

AbstractFullPdf
Nov 2020386042
Dec 20203709
Jan 20215408
Feb 2021126022
Mar 2021173020
Apr 2021182026
May 202143029
Jun 20210031
Jul 20210038
Aug 20210053
Sep 20210046
Oct 2021418072
Nov 2021690050
Dec 2021626033
Jan 2022506066
Feb 2022472042
Mar 2022606053
Apr 2022682073
May 2022796068
Jun 2022676071
Jul 2022638048
Aug 2022724067
Sep 2022898076
Oct 202218040154
Nov 202210580135
Dec 202224160268
Jan 202311800128
Feb 202312400151
Mar 202311260138
Apr 202315780194
May 202310620134
Jun 20239840118
Jul 20239620128
Aug 202312650128
Sep 2023878093
Oct 20231322086
Nov 20231420091
Dec 2023766067
Jan 2024384035
Feb 2024454056
Mar 2024744070
Apr 2024860062
May 2024490028
Jun 2024511067
Jul 2024568059
Aug 2024591068
Sep 2024416048
Oct 2024380052
Nov 2024338033
Dec 2024362058
Jan 2025424049
Feb 2025126062
Mar 20250033
Apr 20250043
May 20250038
Jun 20250028
Jul 2025001
Total3444203946